Related references
Note: Only part of the references are listed.Identification of PIKfyve kinase as a target in multiple myeloma
Cecilia Bonolo de Campos et al.
HAEMATOLOGICA (2020)
Advancing precision medicine with personalized drug screening
Kirill Gorshkov et al.
DRUG DISCOVERY TODAY (2019)
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
Shannon M. Matulis et al.
LEUKEMIA (2019)
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
Andrzej J. Jakubowiak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Current Developments in Immunotherapy in the Treatment of Multiple Myeloma
Martin Koehler et al.
CANCER (2018)
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The multiple myelomas - current concepts in cytogenetic classification and therapy
Shaji K. Kumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J. Bahlis et al.
BLOOD (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Christine Chen et al.
BLOOD (2018)
Personalized Cancer Models for Target Discovery and Precision Medicine
Carla Grandori et al.
TRENDS IN CANCER (2018)
Novel investigational drugs active as single agents in multiple myeloma
Mattia D'Agostino et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Klaus Podar et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Utilizing next-generation sequencing in the management of multiple myeloma
Marta Lionetti et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy
David Dingli et al.
MAYO CLINIC PROCEEDINGS (2017)
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Chantal Pauli et al.
CANCER DISCOVERY (2017)
The therapeutic potential of cell cycle targeting in multiple myeloma
Anke Maes et al.
ONCOTARGET (2017)
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
Muntasir Mamun Majumder et al.
ONCOTARGET (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau et al.
BLOOD (2017)
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Saurabh Chhabra
PHARMACEUTICALS (2017)
Treating Multiple Myeloma Patients With Oral Therapies
Shaji K. Kumar et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma
Sophia Gayle et al.
BLOOD (2017)
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Viktoras Frismantas et al.
BLOOD (2017)
Integrating functional genomics to accelerate mechanistic personalized medicine
Jeffrey W. Tyner
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Zuguang Gu et al.
BIOINFORMATICS (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
K. M. Kortuem et al.
BLOOD CANCER JOURNAL (2016)
New investigational drugs with single-agent activity in multiple myeloma
A. M. Rajan et al.
BLOOD CANCER JOURNAL (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkBa and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Joel G. Turner et al.
ONCOTARGET (2016)
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P)
K. M. Kortuem et al.
ANNALS OF HEMATOLOGY (2015)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in-17p high risk disease
Klaus M. Kortuem et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Yang Liao et al.
BIOINFORMATICS (2014)
The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation
Jean-Pierre A. Kocher et al.
BIOINFORMATICS (2014)
MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing
Krishna R. Kalari et al.
BMC BIOINFORMATICS (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Functional Genomics for Personalized Cancer Therapy
Jeffrey W. Tyner
SCIENCE TRANSLATIONAL MEDICINE (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Targeting the BRAF V600E Mutation in Multiple Myeloma
Mindaugas Andrulis et al.
CANCER DISCOVERY (2013)
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Tea Pemovska et al.
CANCER DISCOVERY (2013)
RSeQC: quality control of RNA-seq experiments
Liguo Wang et al.
BIOINFORMATICS (2012)
Carfilzomib: a novel second-generation proteasome inhibitor
Meaghan L. Khan et al.
FUTURE ONCOLOGY (2011)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul Richardson et al.
BLOOD (2009)
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
Donna E. Reece et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
